

Ministerio de Salud Pública
Instituto Nacional de Salud
Departamento Técnico
Farmacia
341/76
A/jan
16

0752

29 MAR. 1976

390

2

SANTIAGO,

VISTOS: la presentación de D. Oriana Miranda V., Químico Farmacéutico, Director Técnico y en representación de la firma Laboratorio Benguerel propietaria del Laboratorio de Productos Farmacéuticos, ubicada en calle Plaza Valdivieso Solar N° 2409 de esta ciudad, por la que solicita autorización y registro del producto farmacéutico OLIBENCLAMIDA comprimidos, para los efectos de su fabricación y venta en el país; el Acuerdo de la Comisión Técnica Asesora de esta Dirección General, que dió su conformidad, y

TENIENDO PRESENTE: que se han cumplido las disposiciones del Código Sanitario y del Reglamento de Productos Farmacéuticos, Alimentos de Uso Médico y Cosméticos; el Decreto N° 460 de 28 de Noviembre de 1974 del Ministerio de Salud, la Resolución N° 2171 de 13 de Febrero de 1975, de esta Dirección General; el Decreto N° 428 de 26 de Septiembre de 1975 del Ministerio de Salud y las atribuciones conferidas por Resolución N° 2011 del 2 de Septiembre de 1960, del Director General de Salud; dicto la siguiente;

RESOLUCION :

1.- AUTORIZASE a la firma Laboratorio Benguerel propietaria del Laboratorio de Productos Farmacéuticos ubicada en calle Plaza Valdivieso Solar N° 2409 de esta ciudad, representada para estos efectos, por el Director Técnico del Establecimiento Químico Farmacéutico D. Oriana Miranda V., para fabricar y vender el producto farmacéutico OLIBENCLAMIDA comprimidos.

2.- INSCRIBASE el producto que por la presente Resolución se autoriza, bajo el N° 12753 del Registro Nacional de Productos Farmacéuticos, Alimentos de Uso Médico y Cosméticos.

3 ESTABLECESE que la fórmula autorizada corresponde a la siguiente composición y en la forma que se indica:

Cada comprimido contiene:

//.


N-4-2-(5-cloro-2 metoxibenzamida)-etil-fenilsulfonil-N'-ciclohexenil urea (Glibenclanida) 5,0 mg
Lactosa 80,0 mg
Almidón de maíz 70,0 mg
Talco 3,0 mg
Aerosil 2,0 mg
Estearato de Magnesio 0,5 mg

Presentación : Frasco con 30 comprimidos.

Condición de venta : BAJO RECETA MEDICA en Establecimientos -
Tipo A.

4.- DISPONESE que los rótulos de los envases autorizados deben corresponder exactamente en su texto y distribución a lo aceptado en el anexo timbrado de la presente Resolución, copia del cual se adjunta a ella para su cumplimiento, de acuerdo a instrucciones impartidas en Resolución N° 2171 de 13 de Febrero de 1975, de esta Dirección General sobre "Hipoglucemiantes orales".


ANOTESE Y COMUNIQUESE


DRA EDITH RAMIREZ COX
JEFE SECCION FARMACIA
SUBROGANTE

DISTRIBUCION:

- Interesado
- Farmacia (2)
- Inst. Bacte. Chile
- Minist. Economía
- Archivo.-

TRANSCRITO FIELMENTE


SR POLIDORO PALMA VERGARA
MINISTRO DE FE

Nº Ref.:RR814293/16

GZR/JON/pgg

RESOLUCIÓN EXENTA RW Nº 21956/16

Santiago, 19 de octubre de 2016

VISTO ESTOS ANTECEDENTES: la Resolución Exenta RW Nº 10987 de fecha 26 de junio de 2015, por la que se autorizó modificación de fórmula para el producto farmacéutico GLIBENCLAMIDA COMPRIMIDOS 5 mg, Registro Sanitario Nº F-2414/14; el Informe Técnico de Rectificación Nº 2627, emitido por la Unidad de Metodologías Analíticas, concedido a Laboratorios Andrómaco S.A.;

CONSIDERANDO: Que la rectificación solicitada, ha sido motivada por error del titular.

TENIENDO PRESENTE: las disposiciones del artículo 96º del Código Sanitario; el Reglamento del Sistema Nacional de Control de Productos Farmacéutico, aprobado por el Decreto Supremo Nº 3 de 2010 del Ministerio de Salud; en uso de las facultades que me confieren los artículos 59º letra b) y 61º letra b), del Decreto con Fuerza de Ley Nº 1, de 2005 y las facultades delegadas por la Resolución Exenta Nº 292 de 12 de febrero de 2014 del Instituto de Salud Pública de Chile, dicto la siguiente:

R E S O L U C I Ó N

1.- **RECTIFÍCASE** la Resolución Exenta RW Nº 10987 de fecha 26 de junio de 2015, referencia Nº MA643426, para el producto farmacéutico GLIBENCLAMIDA COMPRIMIDOS 5 mg, registro sanitario NºF-2414/14 en el sentido de establecer que las especificaciones del producto terminado (código: MUA-0215-08) corresponden al anexo timbrado adjunto a la presente resolución:

ANÓTESE Y COMUNÍQUESE

JEFA (S) SUBDEPTO. REGISTRO Y AUTORIZACIONES SANITARIAS
AGENCIA NACIONAL DE MEDICAMENTOS
INSTITUTO DE SALUD PÚBLICA DE CHILE

Q.F. XIMENA GONZÁLEZ FRUGONE

**JEFA (S) SUBDEPARTAMENTO REGISTRO Y AUTORIZACIONES SANITARIAS
DEPARTAMENTO AGENCIA NACIONAL DE MEDICAMENTOS
INSTITUTO DE SALUD PÚBLICA DE CHILE**


DISTRIBUCIÓN:
INTERESADO
UCD




Transcrito Fielmente
Ministro de Fe

	METODOLOGIA DE ANALISIS	Código: MUA-0215-08 Página 1 de 1
	GLIBENCLAMIDA COMPRIMIDOS 5 mg	Fecha Emisión: 02-2015 Fecha Expiración: 02-2017
DESARROLLO DE METODOS – INVESTIGACION Y DESARROLLO		Reemplaza: MUA-0215-07

RR 814293

**4. ESPECIFICACIONES DEL PRODUCTO****ESPECIFICACIONES DE REGISTRO**

ASPECTO	Comprimidos circulares, biconvexos, con ranura en una cara, color celeste claro a celeste claro levemente moteado.
PESO	100,0 mg $\pm$ 10%
DIMENSIONES	Diametro 6,5 mm $\pm$ 0,5mm Espesor 2,9 mm $\pm$ 0,5mm
DUREZA	Entre 2 – 14 Kp
FRIABILIDAD	Menor al 1%
IDENTIDAD	Glibenclamida positivo (HPLC)
VALORACION	Valor teórico: 5,0 mg de Glibenclamida / comp Límites: 4,5 – 5,5 mg/comp. 90,0 – 110,0%VD (HPLC)
UNIFORMIDAD DE DOSIS UNITARIA	Cumple requerimientos USP 38 (10 ó 30 comprimidos)
DISOLUCIÓN	Mínimo 70% (Q) disuelto a los 45 minutos. 500 mL Solución amortiguadora borato 0,05M de pH 9,5 USP N° 2 (paletas), 75 rpm.
SUSTANCIAS RELACIONADAS	Glibenclamida Compuesto Relacionado A: No más de 5,3%
ENVASE:	Estuche de cartulina estucada e impresa o caja de cartón etiquetada, conteniendo sistema blister pack PVC incoloro o ámbar/aluminio o blister pack PVDC incoloro o ámbar/aluminio. Todo debidamente impreso, sellado y con folleto de información al paciente.

INSTITUTO DE SALUD PÚBLICA DE CHILE AGENCIA NACIONAL DE MEDICAMENTOS SUBDEPTO. REGISTRO Y AUTORIZACIONES SANITARIAS OFICINA METODOLOGÍAS ANALÍTICAS	
19 OCT. 2016 MUA-0215-08	
N° Ref.:	RR814293/16
N° Registro:	F-2419/14
Firma Profesional:	<i>[Firma]</i>

ESPECIFICACIONES DE ESTABILIDAD**CONTROL MICROBIOLÓGICO:**

Recuento total:	$\leq$ 100 ufc/g
Recuento de Hongos y Levaduras:	$\leq$ 100 ufc/g
S. Aureus, P. aeruginosa	Ausentes
Salmonella y E. Coli	Ausentes

RESEARCH

Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis



OPEN ACCESS

Montserrat Balsells *registrar in endocrinology and nutrition*¹, Apolonia García-Patterson *registrar in endocrinology and nutrition*², Ivan Solà *associate researcher*^{3,4,5}, Marta Roqué *associate researcher*^{3,4,5}, Ignasi Gich *associate researcher*^{5,6,7}, Rosa Corcoy *assistant professor in endocrinology and nutrition*^{2,8,9}

¹Department of Endocrinology and Nutrition, Hospital Universitari Mútua de Terrassa, Terrassa 8821, Spain; ²Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Barcelona 08025, Spain; ³Iberoamerican Cochrane Centre, Hospital de la Santa Creu i Sant Pau, Barcelona; ⁴Institute of Biomedical Research (IIB Sant Pau), Hospital de la Santa Creu i Sant Pau Barcelona; ⁵CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid 28029, Spain; ⁶Department of Epidemiology, Hospital de la Santa Creu i Sant Pau, Barcelona; ⁷Department of Clinical Pharmacology and Therapeutics, Universitat Autònoma de Barcelona, Bellaterra 08193 (Cerdanyola del Vallès), Spain; ⁸CIBER Bioengineering, Biomaterials and Nanotechnology (CIBER-BBN), Instituto de Salud Carlos III, Madrid; ⁹Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra

Abstract

Objective To summarize short term outcomes in randomized controlled trials comparing glibenclamide or metformin versus insulin or versus each other in women with gestational diabetes requiring drug treatment.

Design Systematic review and meta-analysis.

Eligibility criteria for selecting studies Randomized controlled trials that fulfilled all the following: (1) published as full text; (2) addressed women with gestational diabetes requiring drug treatment; (3) compared glibenclamide v insulin, metformin v insulin, or metformin v glibenclamide; and (4) provided information on maternal or fetal outcomes.

Data sources Medline, CENTRAL, and Embase were searched up to 20 May 2014.

Outcomes measures We considered 14 primary outcomes (6 maternal, 8 fetal) and 16 secondary (5 maternal, 11 fetal) outcomes.

Results We analyzed 15 articles, including 2509 subjects. Significant differences for primary outcomes in glibenclamide v insulin were obtained in birth weight (mean difference 109 g (95% confidence interval 35.9 to 181)), macrosomia (risk ratio 2.62 (1.35 to 5.08)), and neonatal hypoglycaemia (risk ratio 2.04 (1.30 to 3.20)). In metformin v insulin, significance was reached for maternal weight gain (mean difference -1.14 kg (-2.22 to -0.06)), gestational age at delivery (mean difference -0.16 weeks (-0.30 to -0.02)), and preterm birth (risk ratio 1.50 (1.04

to 2.16)), with a trend for neonatal hypoglycaemia (risk ratio 0.78 (0.60 to 1.01)). In metformin v glibenclamide, significance was reached for maternal weight gain (mean difference -2.06 kg (-3.98 to -0.14)), birth weight (mean difference -209 g (-314 to -104)), macrosomia (risk ratio 0.33 (0.13 to 0.81)), and large for gestational age newborn (risk ratio 0.44 (0.21 to 0.92)). Four secondary outcomes were better for metformin in metformin v insulin, and one was worse for metformin in metformin v glibenclamide. Treatment failure was higher with metformin than with glibenclamide.

Conclusions At short term, in women with gestational diabetes requiring drug treatment, glibenclamide is clearly inferior to both insulin and metformin, while metformin (plus insulin when required) performs slightly better than insulin. According to these results, glibenclamide should not be used for the treatment of women with gestational diabetes if insulin or metformin is available.

Systematic review registration NCT01998113

Introduction

Gestational diabetes is a common complication of pregnancy, and prevalence is increasing.¹ The standard therapy for women with gestational diabetes requiring drug treatment is insulin. However, since the seminal trial by Langer et al comparing glibenclamide (glyburide) with insulin,² oral agents have been

Correspondence to: R Corcoy, Servei d'Endocrinologia i Nutrició, Hospital de la Santa Creu i Sant Pau, Avinguda Sant Antoni Maria Claret 167, Barcelona 08025, Spain rcorcoy@santpau.cat

Extra material supplied by the author (see <http://www.bmj.com/content/350/bmj.h102?tab=related#datasupp>)

Supplementary tables 1–6 and supplementary figures 1–2

increasingly viewed as potential alternatives. Several observational and randomized controlled trials have addressed the use of oral agents in gestational diabetes, mainly glibenclamide and metformin.³⁻⁶ Although neither glibenclamide nor metformin have marketing authorization for their use in pregnancy, their use as an adjunct therapy in gestational diabetes has been considered by several guidelines. For example, glibenclamide has been acknowledged in the Fifth International Workshop-Conference in Gestational Diabetes Mellitus,⁷ and both glibenclamide and metformin are considered in National Institute for Health and Care Excellence (NICE) guidance⁸ and American College of Obstetricians and Gynecologists (ACOG) practice bulletin.⁹ Oral agents are an attractive alternative to insulin for their easier administration, lower cost, and better acceptance.¹⁰ Use of oral agents is increasing, and in some settings they are the first option when drug treatment is required for women with gestational diabetes.^{6 11-13} In a large nationwide retrospective cohort study in the US including 10 778 women with drug treated gestational diabetes, use of glibenclamide increased from 7.4% in 2000 to 64.5% in 2011, becoming the most common treatment since 2007.¹²

In recent years, several systematic reviews and meta-analyses have summarized the published evidence using different approaches: combining randomized controlled trials and observational studies addressing glibenclamide,¹⁴ performing a meta-analysis of randomized controlled trials comparing glibenclamide with insulin,¹⁵ combining randomized controlled trials addressing glibenclamide or metformin versus insulin in a single meta-analysis,¹⁶ and conducting a meta-analysis of randomized controlled trials comparing metformin with insulin.¹⁷ In 2013, the meta-analysis by Gui and colleagues, which included five randomized controlled trials comparing metformin with insulin, showed differences favouring metformin in terms of maternal weight gain and pregnancy induced hypertension but favouring insulin in terms of gestational age at delivery and preterm birth.¹⁷ A later meta-analysis addressing metformin versus insulin added a non-randomized controlled trial study.¹⁸ In 2014, the meta-analysis of Zeng and colleagues, including five randomized controlled trials comparing glibenclamide with insulin, showed differences favouring glibenclamide in terms of maternal hypoglycaemia but favouring insulin in terms of birth weight, macrosomia, and neonatal hypoglycaemia.¹⁵ As yet, randomized controlled trials comparing glibenclamide or metformin with insulin, or metformin with glibenclamide, have not been addressed in a comprehensive systematic review that evaluates the most relevant maternal and fetal outcomes.

The aim of the present study was to compare risks and benefits of insulin, glibenclamide, and metformin in terms of short term outcomes when used for women with gestational diabetes requiring drug treatment. By means of a systematic review, we synthesized the available evidence concerning short term maternal and fetal outcomes in randomized controlled trials that compared glibenclamide with insulin, metformin with insulin, or metformin with glibenclamide in women with gestational diabetes requiring drug treatment.

Methods

Literature search and study selection

The protocol of this systematic review was registered in ClinicalTrials.gov (NCT01998113), and endorses PRISMA. A comprehensive electronic search strategy was conducted in Medline, Cochrane Central Register of Controlled Trials, and Embase (see supplementary table 1). The last search update was performed on 20 May 2014. Bibliographies from relevant studies

were reviewed, and authors of potentially eligible studies were contacted when necessary to request further information regarding study design or primary outcomes.

Studies were eligible if they fulfilled all the following: (1) they were randomized controlled trials; (2) subjects were women with gestational diabetes requiring drug treatment; (3) they compared glibenclamide with insulin, metformin with insulin, or metformin with glibenclamide; (4) they provided information on one or more maternal or fetal outcome; and (5) they were published as a full paper. The exclusion criterion was a significant overlap with other articles by the same group.

Data collection and outcomes

We pre-specified maternal and fetal outcomes of interest. Primary outcomes were defined as those considered relevant or commonly reported. Primary maternal outcomes were HbA_{1c} level in the third trimester, severe maternal hypoglycaemia, pre-eclampsia, total weight gain during pregnancy, caesarean section, and (for trials comparing metformin v glibenclamide) treatment failure. Primary fetal outcomes were gestational age at delivery, preterm birth, birth weight, macrosomia (≥ 4000 g), large for gestational age newborn (birth weight >90 th centile), small for gestational age newborn (birth weight <10 th centile), any neonatal hypoglycaemia, and perinatal mortality.

Secondary maternal outcomes were fasting and postprandial blood glucose, weight gain since study entry, pregnancy induced hypertension, and induction of labour. Secondary fetal outcomes were fetal hyperinsulinism (measured as either cord C peptide or cord insulin), abnormal Apgar score at 1 and 5 minutes, obstetric trauma, severe neonatal hypoglycaemia (as defined by authors, or requiring intravenous glucose or admission to the neonatal intensive care unit), neonatal jaundice, significant respiratory distress (described as respiratory distress syndrome or requiring respiratory support), stillbirth, neonatal mortality, and admission to the neonatal intensive care unit.

Two investigators independently screened abstracts, reviewed the full text, decided on eligibility, and collected data using a previously designed form. Discrepancies were solved after reviewing the source and by consensus with a third investigator. The risk of bias was assessed at the study level taking into account the randomization process, quality of allocation concealment, blinding, selective outcome reporting, sample size calculation, attrition rates, intention-to-treat analysis, and comparability of subjects' baseline characteristics (maternal age, pre-pregnancy body mass index, fasting plasma glucose concentration and two hours after oral glucose tolerance test, gestational age, and HbA_{1c} level at study entry).¹⁹ This assessment was essentially qualitative, except in the case of attrition rates where we predefined a quantitative criterion: a cut-off of 15% both for overall attrition rate and for differences between treatment groups (unless otherwise foreseen by the authors). This information concerning risk of bias was used to perform sensitivity analyses, excluding articles with relevant weaknesses in trial design or execution. Unbalanced baseline characteristics alone were not considered an exclusion criterion for the sensitivity analysis.

Statistical analysis

Outcome data from original studies were pooled into either relative risks for dichotomous outcomes or mean differences for continuous outcomes using Review Manager 5.1 software. Heterogeneity was explored for all the meta-analyses. Analyses were undertaken using a fixed effects model; in case of substantial heterogeneity ($I^2 \geq 50\%$) a random effects model was

used. Pooled analyses were also used to compare baseline characteristics. In the metformin versus glibenclamide comparison including two studies, we performed a qualitative assessment of the effects (direction, magnitude, and precision) in addition to the meta-analysis.

In the metformin versus insulin comparison, the only baseline characteristic that presented significant and relevant differences between treatment groups was body mass index. Thus, for this comparison we performed a meta-regression to explore baseline body mass index as a source of heterogeneity by means of meta-regression models. Post hoc meta-regression models were built for variables known to be influenced by maternal body mass index and with heterogeneity >10% (weight gain, caesarean section, macrosomia, and a large for gestational age newborn), considering the average baseline difference in body mass index between treatments as the independent factor.

In the three drug comparisons, we calculated average treatment failure (%) for oral agents. In the metformin versus glibenclamide comparison, we also calculated the pooled estimate for treatment failure in terms of risk ratio.

Publication bias was assessed for all analyses after visual inspection of funnel plots.

Results

The search retrieved 974 abstracts. As depicted in the flow chart (supplementary figure 1), 15 studies fulfilled our inclusion criteria—seven comparing glibenclamide with insulin (798 subjects), six comparing metformin with insulin (1362 subjects), and two comparing metformin with glibenclamide (349 subjects). The characteristics of the included studies and quality assessment are described in supplementary tables 2 and 3. Meta-analysis results for each comparison are presented in tables 1–3. Forest plots for primary outcomes with significant differences in any of the meta-analyses are shown as supplementary figure 2, with the exception of those for birth weight and any neonatal hypoglycaemia, which are displayed in figures 1 and 2.

Glibenclamide versus insulin

Characteristics of the seven included studies and baseline data are summarized in supplementary table 2.^{2 3 20–24} Studies were performed in the US, Brazil, and India. Most common diagnostic criteria were those of Carpenter and Coustan and of the World Health Organization, and blood glucose cut-off values for initiating drug treatment were similar among trials. The largest study² included 404 subjects, while each of the other six included fewer than 100 participants. Baseline characteristics did not differ between groups (see supplementary table 4).

All trials were open label, and none had a published protocol. Randomization procedure, allocation concealment, and sample size calculation were not available for any of the studies. Three studies reported one variable less than indicated in the methods.^{2 20–24} Two studies had attrition issues: one had a high balanced attrition, but, as this had been foreseen by the authors,³ the study was not excluded in the sensitivity analysis; the other study had an unbalanced attrition rate (3/13 (23.1%) v 0/13) (see supplementary table 3)²¹ and was excluded in the sensitivity analysis.

When compared with insulin, glibenclamide was associated with a higher birth weight (pooled mean difference 109 g (95% confidence interval 35.9 to 181)) and more macrosomia (pooled risk ratio 2.62 (1.35 to 5.08)) and neonatal hypoglycaemia (pooled risk ratio 2.04 (1.30 to 3.20)). The average treatment

failure in the glibenclamide group was 6.37% (20/314). None of the secondary outcomes showed significant differences (table 1). The sensitivity analysis did not affect treatment estimates in any substantial way (see supplementary table 5), and funnel plots displayed symmetrical distributions for all the outcomes with the exception of large for gestational age.

Outcome definition and active ascertainment were not always provided. In some outcomes such as preterm birth, caesarean section, birth weight, and Apgar score there is wide agreement in their definition. In those where definition and detection protocol can display more differences (neonatal hypoglycaemia, respiratory distress, jaundice, and admission to the neonatal intensive care unit), reported definitions and active ascertainment were reasonably similar with the exception of the protocol to detect neonatal hypoglycaemia with measurements of glycaemia ranging from two to nine.

In addition to primary and secondary outcomes, maternal biochemical hypoglycaemia was reported to be higher in the insulin group by Langer et al,² whereas Ogunyemi et al²² reported a similar rate in both groups. Ogunyemi et al also described additional side effects in 6.3% of patients treated with glibenclamide.

Metformin versus insulin

Characteristics of the six included studies and baseline data are summarized in supplementary table 2.^{4 25–29} Studies were performed in the US, Australia and New Zealand, Finland, Iran, and Brazil. Several diagnostic criteria were used, and blood glucose cut-off values for initiating drug treatment were similar among studies. Metformin and insulin groups were similar in all baseline characteristics, but prepregnancy body mass index was significantly higher in the metformin group (pooled mean difference 0.78 (95% confidence interval 0.15 to 1.41), see supplementary table 4).

All trials were open label, and sample size calculation was described. Published protocol, randomization procedure, and allocation concealment were available for most studies. All the studies reported findings for the outcomes specified in their protocols. Attritions were lower than 15% and balanced among groups in all trials. One study was excluded from the sensitivity analysis²⁵ because of a relevant weakness in trial execution (when we calculated mean height using the reported weight and body mass index in the metformin and insulin groups, we obtained figures of 140 and 160 cm respectively, which is virtually impossible) (see supplementary table 3).

When compared with insulin, metformin was associated with less maternal weight gain (pooled mean difference –1.14 kg (95% confidence interval –2.22 to –0.06)), lower gestational age at delivery (pooled mean difference –0.16 weeks (–0.30 to –0.02)), and more preterm birth (pooled risk ratio 1.50 (1.04 to 2.16)). A trend was observed towards a lower rate of any neonatal hypoglycaemia (pooled risk ratio 0.78 (0.60 to 1.01)). The average treatment failure in the metformin group was 33.8% (229/678). For secondary outcomes, metformin was associated with lower postprandial blood glucose (pooled mean difference –0.14 mmol/L (–0.22 to –0.05)), less maternal weight gain since study entry (pooled mean difference –1.23 kg (–1.72 to –0.73)), less pregnancy induced hypertension (pooled risk ratio 0.53 (0.31 to 0.90)), and less severe neonatal hypoglycaemia (pooled risk ratio 0.62 (0.42 to 0.94)) (table 2). The sensitivity analysis did not affect treatment estimates in any substantial way (see supplementary table 6), and funnel plots displayed symmetrical distributions for all the outcomes, with the exception of maternal weight gain and weight gain since study

entry. Outcome definition and active ascertainment were not always provided. In outcomes where definition and detection protocol can display more differences, reported definitions and active ascertainment were reasonably similar, with the exception of the protocol to detect neonatal hypoglycaemia with measurements of glycaemia ranging from one to more than six.

Baseline maternal body mass index continued to be higher in the metformin group in the sensitivity analysis (pooled mean difference 0.68 (0.05 to 1.32)). Baseline differences in body mass index were not significant in any meta-regression model, suggesting that this variable is unlikely to be a source of heterogeneity in the meta-analysis results.

In addition to primary and secondary outcomes, maternal biochemical hypoglycaemia was not reported in any study. Additional side effects in the metformin group (mainly gastrointestinal) were reported in five studies, ranging from 2.5% to 45.7%.^{4 26-29} Nevertheless, patients preferred metformin over insulin in the two studies that addressed patient satisfaction.^{4 25}

Metformin versus glibenclamide

Only two trials compared metformin and glibenclamide head to head, and their characteristics are summarized in supplementary table 2.^{5 30} Studies were performed in the US and Brazil, and diagnostic criteria were those of Carpenter and Coustan³⁰ and the WHO.⁵ Blood glucose cut-off values for initiating drug treatment were lower in one of the trials.⁵ Metformin and glibenclamide groups were similar in baseline characteristics with the exception of higher maternal age (pooled mean difference 1.36 years (95% confidence interval 0.07 to 2.64)) and number of prior pregnancies (pooled mean difference 0.37 pregnancies/patient (0.20 to 0.72)) in the metformin group (see supplementary table 4).

Both trials were open label and described the randomization procedure and allocation concealment. Only one of the studies had a published protocol and described sample size calculation.³⁰ One study reported one variable less than those described in the methods (macrosomia).⁵ There were no attritions (see supplementary table 3), and a sensitivity analysis was not necessary since no study fulfilled criteria for exclusion.

When compared with glibenclamide, metformin was associated with less maternal weight gain (pooled mean difference -2.06 kg (-3.98 to -0.14)), lower birth weight (pooled mean difference -209 g (-314 to -104)), less macrosomia (pooled risk ratio 0.33 (0.13 to 0.81)), and fewer large for gestational age newborns (pooled risk ratio 0.44 (0.21 to 0.92)). The average treatment failure was 26.8% (48/179) in the metformin group versus 23.5% (40/170) in the glibenclamide group. For secondary outcomes, metformin was associated with higher fasting blood glucose during treatment (pooled mean difference 0.15 mmol/L (0.00 to 0.30)) (table 3). Funnel plots displayed symmetrical distributions for all the outcomes with the exception of caesarean section. As to outcomes where definition and detection protocol can display more differences, both authors reported data on neonatal hypoglycaemia (similar definition, protocol for detection reported in one study⁵) and neonatal intensive care unit stay (not defined in either of the studies).

In the qualitative assessment of birth weight, macrosomia, and fasting blood glucose (outcomes addressed in both studies and with significant differences), the direction, magnitude, and precision of the effects were similar with the exception of a wider interval for macrosomia in the study of Moore et al.³⁰

In addition to primary and secondary outcomes, maternal biochemical hypoglycaemia was reported to be similar in both

groups in the study of Moore et al.³⁰ Additional side effects were not reported.

Discussion

The results of our present study in women with gestational diabetes requiring drug treatment show that glibenclamide and metformin do not achieve similar short term outcomes when compared with each other or when compared with insulin.

Glibenclamide versus insulin

The main finding was observed when comparing glibenclamide with insulin. Birth weight was about 100 g higher, neonatal hypoglycaemia was twofold higher, and macrosomia was more than twofold higher in the glibenclamide group. The magnitude of the difference in these outcomes is relevant for clinical practice. In addition, the higher—although not significant—risk ratios for large for gestational age and severe neonatal hypoglycaemia point in the same direction. It is important to note that neonatal hypoglycaemia and macrosomia are included among highest priority outcomes in a study specifically addressing research needs in gestational diabetes.³¹

Higher birth weight^{3 15 20} and higher rates of macrosomia^{3 15} and neonatal hypoglycaemia^{15 20 32} with glibenclamide use had already been reported in individual trials^{3 20} or meta-analyses,^{15 32} but these untoward effects have received little attention to date. For example, the American College of Obstetricians and Gynecologists (ACOG) practice bulletin on gestational diabetes in 2013 indicates that current data show no adverse short term effects from oral diabetic therapy during pregnancy on maternal or neonatal health but that long term outcomes have yet to be studied.⁹ We now report a comprehensive meta-analysis on randomized controlled trials comparing glibenclamide with insulin to provide robust estimators for these outcomes.

The main differences between our present meta-analysis on glibenclamide versus insulin and that by Zeng et al.¹⁵ are, first, that we included two additional papers^{23 24} and, second, that the outcomes addressed in the two meta-analyses were not completely coincident. We did not consider four outcomes included by Zeng and colleagues¹⁵ (non-severe maternal hypoglycaemia, congenital malformations, hypocalcaemia, polycythaemia), but we considered 17 additional ones (maternal total weight gain, maternal weight gain since entry, maternal severe hypoglycaemia, pregnancy induced hypertension, gestational age at delivery, induction, cord C peptide and insulin, Apgar score at 1 and 5 minutes, small for gestational age, obstetric trauma, severe neonatal hypoglycaemia, respiratory distress, and mortality (stillbirth, neonatal, and perinatal)).

Our meta-analysis confirms the results of Zeng et al.,¹⁵ but our interpretation is clearly divergent. Although advising some caution, Zeng et al conclude that glibenclamide is a convenient alternative to insulin in developing countries. We consider that the twofold higher neonatal hypoglycaemia and more than twofold higher macrosomia in women treated with glibenclamide are unacceptable; if an alternative to insulin is required, metformin—with a more favourable short term profile—would be a better option. Our third meta-analysis, comparing metformin with glibenclamide, provides confirmation of the untoward effects of glibenclamide.

Even when the few trials addressing cord insulin or C peptide have not shown any difference, we can only understand the results in the glibenclamide versus insulin comparison in terms of more fetal hyperinsulinism in the glibenclamide arm. As glycaemic control cannot account for this hyperinsulinism, it is

necessary to consider glibenclamide itself. Reports from Langer et al do not support a significant maternal to fetal transfer of glibenclamide² or its metabolites.³³

However Hebert et al³⁴ describe a maternal to fetal ratio for glibenclamide of 0.7. They attribute these diverging results to the use of a method with a detection limit of 0.25 ng/mL,³⁴ while that of the method of Langer et al was 10 ng/mL.² We therefore consider that maternal to fetal transfer of glibenclamide is the most likely explanation for the higher birth weight and risk ratios of macrosomia and neonatal hypoglycaemia observed in the glibenclamide group.

Metformin versus insulin

The meta-analysis of randomized controlled trials comparing metformin with insulin showed differences in seven of the 29 analyzed variables, but the magnitudes were smaller than those for glibenclamide versus insulin. In the metformin group, maternal outcomes were better in terms of total weight gain, weight gain since study entry, postprandial blood glucose, and pregnancy induced hypertension, whereas fetal outcomes were worse in terms of gestational age at delivery and preterm birth and better in terms of severe neonatal hypoglycaemia. Among these variables, weight gain, pregnancy induced hypertension, and neonatal hypoglycaemia are included as highest priority outcomes in a study specifically addressing research needs in gestational diabetes.³¹ Individual trials had previously reported significant differences in the above outcomes (postprandial glycaemia,⁴ gestational age at delivery,⁴ preterm birth,⁴ weight gain,^{4 27} weight gain since study entry,^{4 27 29} neonatal hypoglycaemia,²⁹ and severe neonatal hypoglycaemia⁴) with the exception of pregnancy induced hypertension, that nevertheless reached significance in a recent meta-analysis.¹⁷

The main differences between the meta-analysis by Gui et al¹⁷ and the present study are, first, that we included an additional randomized controlled trial²⁹ and, second, that the outcomes addressed in the two meta-analyses were not completely coincident. We did not consider three outcomes included by Gui et al (congenital malformations, cord pH, and phototherapy),¹⁷ but we considered nine additional ones (maternal total weight gain and severe hypoglycaemia, induction, cord C peptide and insulin, Apgar score at 1 minute, macrosomia, severe neonatal hypoglycaemia, and mortality (stillbirth, neonatal, perinatal)). Our meta-analysis confirms the results of Gui et al¹⁷ and adds a lower total maternal weight gain and a lower occurrence of severe neonatal hypoglycaemia in the metformin group.

It is important to note that, although metformin and insulin groups in the current study were similar in most baseline characteristics, prepregnancy body mass index was higher by 0.78 in the metformin group. It is likely that this higher body mass index influenced outcomes such as pregnancy induced hypertension,³⁵ pre-eclampsia,³⁵ birth weight,³⁵ large for gestational age,³⁵ and neonatal hypoglycaemia.³⁶ If treatment groups had had a similar baseline body mass index, differences in outcomes could have been more apparent (pregnancy induced hypertension, severe neonatal hypoglycaemia) or become significant (pre-eclampsia, birth weight, large for gestational age, any neonatal hypoglycaemia).

Regarding potential mechanisms mediating differences with metformin use, the lower postprandial blood glucose observed with metformin (−0.14 mmol/L) seems insufficient to account for the lower rate in pregnancy induced hypertension and severe neonatal hypoglycaemia.³⁷ The effect of metformin on maternal weight gain could be expected considering the effect of

metformin outside pregnancy, while that on pregnancy induced hypertension could be attributed to improvements in insulin resistance, inflammation, or endothelial function. The effect of metformin on gestational age—small, but sufficient to increase the rate of preterm birth by 50%—is inconsistent with the slightly better postprandial blood glucose and the reduced rate of pregnancy induced hypertension. This effect of metformin on gestational age could be attributed to metformin itself. However, it is of note that in one report in women with polycystic ovary syndrome, metformin treatment was associated with a lower rate of preterm birth,³⁸ and the authors indicated that underlying mechanism(s) could only be speculated on. It should also be pointed out that in our study, and contrary to what might be expected, a lower gestational age at birth in the metformin group was associated with less neonatal hypoglycaemia. Again, an independent effect of metformin could be hypothesized.

Despite the fact that side effects were more common in women treated with metformin, it was the favoured drug in the studies addressing preference.

Metformin versus glibenclamide

The meta-analysis of the two randomized controlled trials comparing metformin with glibenclamide showed differences in five of the 30 analyzed variables. Differences in total maternal weight gain, birth weight, macrosomia, and large for gestational age were roughly the sum of the effects seen in the first two meta-analyses. However, the results in three outcomes were unexpected after the findings of the first two comparisons: in the metformin group, we would expect a lower rate of neonatal hypoglycaemia, no difference for fasting blood glucose, and a higher rate of treatment failure. We have no explanation for the difference in fasting blood glucose, while the lack of significance for neonatal hypoglycaemia and treatment failure could be due to the relatively small number of included subjects. The higher fasting blood glucose in the metformin group (0.15 mmol/L) cannot account for the differences in clinical outcomes, first, because it cannot explain the lower maternal weight gain and, second, because it would have increased outcomes related to birth weight rather than decrease them. Overall, we consider the results of this comparison as confirmatory of the maternal weight gain and outcomes related to birth weight reported in the first two. The results of the qualitative assessment support the results of the meta-analysis for outcomes with significant differences.

Among the variables where significant differences were reached, maternal weight gain, macrosomia, and large for gestational age are included as highest priority outcomes in a study specifically addressing research needs in gestational diabetes.³¹

In the three meta-analyses, and for most outcomes, definition and active ascertainment were not an issue. For outcomes where this could be important, definitions and detection protocol when provided were reasonably similar with the exception of neonatal hypoglycaemia. Nevertheless, heterogeneity was very low for most of these variables.

The main limitation of this study is that we have performed meta-analyses of aggregated patient data, whereas using individual patient data would have allowed better adjustment for baseline characteristics. Its main strength is to be the most comprehensive systematic review and meta-analysis addressing glibenclamide and metformin versus insulin or versus each other in the treatment of women with gestational diabetes requiring drug treatment.

Conclusion

Oral agents are clearly more attractive than insulin to treat women with gestational diabetes, but attainment of similar or better results should be a prerequisite for their use. The results of the three meta-analyses presented here indicate that, in the short term at least, this is not the case for glibenclamide (higher birth weight and more macrosomia and neonatal hypoglycaemia). For metformin, results were better for maternal outcomes in terms of weight gain and pregnancy induced hypertension but uneven for fetal outcomes: more preterm birth and less severe neonatal hypoglycaemia. It is important to bear in mind, however, that metformin is associated with a higher rate of treatment failure and that its long term safety remains unknown.

As to future research, we consider that: (1) meta-analyses of individual patient data would allow adjustment for differences in baseline characteristics, especially important in the comparison of metformin with insulin; (2) although a definite proof of glibenclamide producing more fetal hyperinsulinism is lacking, current evidence discourages further trials using this drug; (3) studies addressing mechanisms underlying earlier delivery and less neonatal hypoglycaemia in women treated with metformin would be of interest.

We conclude that, in the short term, in women with gestational diabetes requiring drug treatment, glibenclamide is clearly inferior to both insulin and metformin while metformin (plus insulin when required) performs slightly better than insulin. According to these results, glibenclamide should not be used for the treatment of women with gestational diabetes if metformin or insulin are available.

We thank Carolyn Newey, author editor that has reviewed the draft written by the authors. We also thank the authors of randomized controlled trials who provided the requested information.

Preliminary results of this study have been presented at the 45th Meeting of the Diabetic Pregnancy Study Group held in Malta in 2013 and at the XXV meeting of the Sociedad Española de Diabetes held in Pamplona in 2014; corresponding abstracts were published in the 45th DPSG abstract book and in *Av Diabetol* 2014;30(Espec Congr):209.

Contributors: RC is the guarantor of this article. She had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. MB, AGP and RC conceived and designed the study, MB and AGP performed data acquisition. MB, AGP, IS, MR, IG and RC analysed and interpreted the data and carried out the statistical analyses. MB, AGP and RC drafted the manuscript. All authors critically revised the manuscript for important intellectual content.

Funding: None. The study sponsor is Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; the sponsor was not involved in the design or execution of the systematic review or in the writing of the manuscript.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/doi_disclosure.pdf and declare: declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, though MB, AGP, and RC have received travel grants from Lilly, NovoNordisk, and Sanofi Aventis; and no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Not required

- Hunt KJ, Schuller KL. The increasing prevalence of diabetes in pregnancy. *Obstet Gynecol Clin North Am* 2007;34:173-99.
- Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. *N Engl J Med* 2000;343:1134-8.

- Lain KY, Garabedian MJ, Daftary A, Jeyabalan A. Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. *Am J Obstet Gynecol* 2009;200:501.e501-506.
- Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. *N Engl J Med* 2008;358:2003-15.
- Silva JC, Fachin DR, Coral ML, Bertini AM. Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. *J Perinat Med* 2012;40:225-8.
- Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. *Am J Obstet Gynecol* 2005;193:118-24.
- Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. *Diabetes Care* 2007;30(suppl 2):S251-60.
- National Institute for Health and Care Excellence. Diabetes in pregnancy: management of diabetes and its complications from pre-conception to the postnatal period. (Clinical guideline 63.) 2008. www.nice.org.uk/guidance/cg63/.
- Committee on Practice Bulletins—Obstetrics. Practice bulletin No. 137: gestational diabetes mellitus. *Obstet Gynecol* 2013;122:406-16.
- Coetzee EJ. Pregnancy and diabetes scenario around the world: Africa. *Int J Gynaecol Obstet* 2009;104:S39-41.
- Goh JE, Sadler L, Rowan J. Metformin for gestational diabetes in routine clinical practice. *Diabetic Med* 2011;28:1082-7.
- Camelo Castillo W, Boggess K, Sturmer T, Brookhart MA, Benjamin DK Jr, Jonsson Funk M. Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. *Obstet Gynecol* 2014;123:177-84.
- Heilmair C, Thielscher C, Ziller M, Altmann V, Kostev K. Use of antidiabetic agents in the treatment of gestational diabetes mellitus in Germany, 2008-2012. *J Obstet Gynaecol Res* 2014;40:1592-7.
- Moretti ME, Rezvani M, Koren G. Safety of glyburide for gestational diabetes: a meta-analysis of pregnancy outcomes. *Ann Pharmacother* 2008;42:483-90.
- Zeng YC, Li MJ, Chen Y, Jiang L, Wang SM, Mo XL, et al. The use of glyburide in the management of gestational diabetes mellitus: a meta-analysis. *Adv Med Sci* 2014;59:95-101.
- Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis. *Am J Obstet Gynecol* 2010;203:457.e1-9.
- Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. *PLoS One* 2013;8:e64585.
- Su DF, Wang XY. Metformin vs insulin in the management of gestational diabetes: a systematic review and meta-analysis. *Diabetes Res Clin Pract* 2014;104:353-7.
- Higgins JPT, Altman DG, Sterne JAC, eds. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*. Cochrane Collaboration, 2011. www.cochrane-handbook.org.
- Silva JC, Bertini AM, Taborda W, Becker F, Beber FR, Aquim GM, et al. [Glibenclamide in the treatment for gestational diabetes mellitus in a compared study to insulin]. *Arq Bras Endocrinol Metabol* 2007;51:541-6.
- Anjalakshi C, Balaji V, Balaji MS, Seshiah V. A prospective study comparing insulin and glibenclamide in gestational diabetes mellitus in Asian Indian women. *Diabetes Res Clin Pract* 2007;76:474-5.
- Ogunyemi D, Jesse M, Davidson M. Comparison of glyburide versus insulin in management of gestational diabetes mellitus. *Endocr Pract* 2007;13:427-8.
- Mukhopadhyay P, Bag TS, Kyal A, Saha DP, Khalid N. Oral hypoglycemic glibenclamide: can it be a substitute to insulin in the management of gestational diabetes mellitus? A comparative study. *J SAGOG* 2012;4:28-31.
- Tempe A, Mayanglambam RD. Glyburide as treatment option for gestational diabetes mellitus. *J Obstet Gynaecol Res* 2013;39:1147-52.
- Moore LE, Briery CM, Clokey D, Martin RW, Williford NJ, Bofill JA et al. Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison. *J Reprod Med* 2007;52:1011-5.
- Ijas H, Vaarasmaki M, Morin-Papunen L, Keravuo R, Ebeling T, Saarela T, et al. Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study. *BJOG* 2011;118:880-5.
- Niromanesh S, Alavi A, Sharbaf FR, Amjadi N, Moosavi S, Akbari S. Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial. *Diabetes Res Clin Pract* 2012;98:422-9.
- Tertti K, Ekblad U, Koskinen P, Vahlberg T, Ronnemaa T. Metformin vs. insulin in gestational diabetes. A randomized study characterizing metformin patients needing additional insulin. *Diabetes Obes Metab* 2013;15:246-51.
- Spaulonci CP, Bernardes LS, Trindade TC, Zugaib M, Francisco RP. Randomized trial of metformin vs insulin in the management of gestational diabetes. *Am J Obstet Gynecol* 2013;209:34.e1-7.
- Moore LE, Clokey D, Rappaport VJ, Curet LB. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. *Obstet Gynecol* 2010;115:55-9.
- Bennett WL, Robinson KA, Saldanha IJ, Wilson LM, Nicholson WK. High priority research needs for gestational diabetes mellitus. *J Womens Health* 2012;21:925-32.
- Waugh N, Royle P, Clar C, Henderson R, Cummins E, Hadden D, et al. Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee. *Health Technol Assess* 2010;14:1-183.
- Elliott BD, Langer O, Schenker S, Johnson RF. Insignificant transfer of glyburide occurs across the human placenta. *Am J Obstet Gynecol* 1991;165:807-12.
- Hebert MF, Ma X, Narahariseti SB, Krudys KM, Umans JG, Hankins GD, et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. *Clin Pharmacol Ther* 2009;85:607-14.
- Siega-Riz AM, Siega-Riz AM, Laraia B. The implications of maternal overweight and obesity on the course of pregnancy and birth outcomes. *Maternal Child Health J* 2006;10(5 suppl):S153-6.
- Garcia-Patterson A, Aulinas A, Maria MA, Ubeda J, Orellana I, Ginovart G, et al. Maternal body mass index is a predictor of neonatal hypoglycemia in gestational diabetes mellitus. *J Clin Endocrinol Metab* 2012;97:1623-8.
- International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care* 2010;33:676-82.

What is already known on this topic

Oral agents are increasingly used to treat gestational diabetes, and current guidelines consider their use even though information on their safety is limited

Although several meta-analyses of randomized controlled trials addressing oral agents have been published, a comprehensive study including glibenclamide versus insulin, metformin versus insulin, and metformin versus glibenclamide has not been performed

What this study adds

In the short term, in women with gestational diabetes requiring drug treatment, glibenclamide is clearly inferior to both insulin and metformin whereas metformin (plus insulin when required) performs slightly better than insulin

- 38 Vanky E, De Zegher F, Diaz M, Ibanez L, Carlsen SM. On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome - an epi-analysis. *Acta Obstet Gynecol Scand* 2012;91:1460-4.

Accepted: 25 November 2014

Cite this as: [BMJ 2015;350:h102](#)

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

Tables

Table 1 | Meta-analysis of randomized controlled trials comparing outcomes from treatment with glibenclamide v insulin in women with gestational diabetes

Outcomes	No of studies	No of patients treated		Mean difference (95% CI)	Relative risk (95% CI)	P value	I ² value
		With glibenclamide	With insulin				
Primary outcomes							
HbA _{1c} level at end of third trimester (%)	3	241	246	−0.03 (−0.25 to 0.18)*	—	0.75	52
Severe maternal hypoglycaemia (%)	4	277	278	—	0 v 0	—	—
Pre-eclampsia (%)	4	275	284	—	0.90 (0.51 to 1.61)	0.73	0
Maternal weight gain (kg)	2	233	239	−0.5 (−1.6 to 0.62)	—	0.38	21
Caesarean section (%)	4	286	297	—	0.89 (0.71 to 1.11)	0.30	3
Gestational age at delivery (weeks)	6	384	391	0.05 (−0.18 to 0.28)	—	0.69	14
Preterm birth (%)	5	316	325	—	0.87 (0.57 to 1.33)	0.52	0
Birth weight (g)	7	394	404	109 (35.9 to181)	—	0.003	0
Macrosomia (%)	6	346	355	—	2.62 (1.35 to 5.08)	0.004	34
Large for gestational age (%)	5	314	323	—	1.87 (0.76 to 4.61)*	0.17	52
Small for gestational age (%)	4	284	293	—	1.01 (0.56 to 1.82)	0.97	9
Any neonatal hypoglycaemia (%)	7	386	400	—	2.04 (1.30 to 3.20)	0.002	0
Perinatal mortality (%)	3	277	287	—	1.45 (0.29 to 7.21)	0.65	0
Secondary outcomes							
Fasting blood glucose (mmol/L)	3	274	280	0.06 (−0.06 to 0.19)	—	0.33	0
Postprandial blood glucose (mmol/L)	4	284	293	0.08 (−0.08 to 0.24)	—	0.34	0
Maternal weight gain since entry (kg)	0	—	—	—	—	—	—
Pregnancy induced hypertension (%)	0	—	—	—	—	—	—
Induction (%)	0	—	—	—	—	—	—
Cord C peptide (nmol/L)	1	31	28	0.07 (−0.14 to 0.27)	—	0.63	—
Cord insulin (pmol/L)	3	242	244	−4.31 (−20.4 to 11.7)	—	0.60	0
1 minute Apgar score <7 (%)	0	—	—	—	—	—	—
5 minute Apgar score <7 (%)	0	—	—	—	—	—	—
Obstetric trauma (%)	2	73	77	—	0 v 0	—	—
Severe neonatal hypoglycaemia† (%)	3	81	90	—	5.31 (0.63 to 44.9)	0.13	0
Neonatal jaundice (%)	4	271	278	—	1.44 (0.68 to 3.06)	0.34	0
Neonatal respiratory distress syndrome (%)	2	231	233	—	0.61 (0.19 to 1.92)	0.39	0
Stillbirth (%)	5	317	326	—	1.60 (0.46 to 5.49)	0.46	0
Neonatal mortality (%)	2	244	251	—	1.01 (0.06 to 16.0)	0.99	—
NICU admission (%)	4	302	306	—	0.97 (0.56 to 1.69)	0.92	0

I²=Heterogeneity. HbA_{1c}= glycated haemoglobin. NICU=neonatal intensive care unit.

*Estimated using a random effects model because I²>50%

†Defined by authors or requiring intravenous glucose or NICU admittance.

Table 2| Meta-analysis of randomized controlled trials comparing outcomes from treatment with metformin v insulin in women with gestational diabetes

Outcomes	No of studies	No of patients treated		Mean difference (95% CI)	Relative risk (95% CI)	P value	I ² value
		With metformin	With insulin				
Primary outcomes							
HbA _{1c} level at end of third trimester (%)	4	508	533	−0.04 (−0.09 to 0.02)	—	0.21	24
Severe maternal hypoglycaemia (%)	4	268	268	—	0 v 0	—	—
Pre-eclampsia (%)	5	646	653	—	0.82 (0.56 to 1.20)	0.32	0
Maternal weight gain (kg)	4	468	505	−1.14 (−2.22 to −0.06)*	—	0.04	64
Caesarean section (%)	6	678	684		0.97 (0.85 to 1.12)	0.71	17
Gestational age at delivery (weeks)	6	678	684	−0.16 (−0.30 to −0.02)	—	0.03	0
Preterm birth (%)	5	646	653	—	1.50 (1.04 to 2.16)	0.03	0
Birth weight (g)	6	678	684	−31.4 (−86.5 to 23.6)	—	0.26	4
Macrosomia (%)	6	678	684	—	0.96 (0.73 to 1.27)	0.80	13
Large for gestational age (%)	5	646	653	—	0.88 (0.69 to 1.11)	0.28	22
Small for gestational age (%)	5	646	653	—	0.88 (0.58 to 1.33)	0.53	0
Any neonatal hypoglycaemia (%)	6	676	684	—	0.78 (0.60 to 1.01)	0.06	0
Perinatal mortality (%)	4	600	607	—	1.0 (0.14 to 7.12)	0.99	0
Secondary outcomes							
Fasting blood glucose (mmol/L)	4	521	527	0.04 (−0.03 to 0.11)	—	0.24	49
Postprandial blood glucose (mmol/L)	4	521	527	−0.14 (−0.22 to −0.05)	—	0.002	38
Maternal weight gain since entry (kg)	4	565	533	−1.23 (−1.72 to −0.73)*	—	<0.001	61
Pregnancy induced hypertension (%)	3	553	557	—	0.53 (0.31 to 0.90)	0.02	0
Induction (%)	3	520	527	—	0.91 (0.81 to 1.02)	0.11	46
Cord C peptide (nmol/L)	0	—	—	—	—	—	—
Cord insulin (pmol/L)	1	220	234	7.64 (−92.7 to 108)	—	0.88	—
1 minute Apgar score <7 (%)	0	—	—	—	—	—	—
5 minute Apgar score <7 (%)	1	363	370	—	3.06 (0.32 to 29.3)	0.33	—
Obstetric trauma (%)	2	472	477	—	0.86 (0.45 to 1.63)	0.64	2
Severe neonatal hypoglycaemia† (%)	3	519	527	—	0.62 (0.42 to 0.94)	0.02	48
Neonatal jaundice (%)	6	677	684	—	0.90 (0.67 to 1.21)	0.47	0
Neonatal respiratory distress syndrome (%)	5	630	634	—	1.30 (0.70 to 2.41)	0.40	0
Stillbirth (%)	5	632	638	—	1.38 (0.27 to 7.02)	0.69	0
Neonatal mortality (%)	4	599	606	—	0 v 0	—	—
NICU admission (%)	5	631	638	—	0.87 (0.70 to 1.09)	0.23	0

I²=Heterogeneity. HbA_{1c}= glycosylated haemoglobin. NICU=neonatal intensive care unit.*Estimated using a random effects model because I²>50%

†Defined by authors or requiring intravenous glucose or NICU admittance.


Table 3| Meta-analysis of randomized controlled trials comparing outcomes from treatment with metformin v glibenclamide in women with gestational diabetes

Outcomes	No of studies	No of patients treated		Mean difference (95% CI)	Relative risk (95% CI)	P value	I ² value
		With metformin	With glibenclamide				
Primary outcomes							
HbA _{1c} level at end of third trimester (%)	1	104	96	−0.11 (−0.34 to 0.12)	—	0.34	—
Severe maternal hypoglycaemia (%)	1	104	96	—	0 v 0	—	—
Pre-eclampsia (%)	2	179	170	—	0.95 (0.28 to 3.25)	0.94	0
Maternal weight gain (kg)	1	104	96	−2.06 (−3.98 to −0.14)	—	0.04	—
Caesarean section (%)	2	179	170	—	1.99 (0.32 to 12.4)*	0.46	84
Treatment failure (%)	2	179	170	—	1.23 (0.42 to 3.54)*	0.71	87
Gestational age at delivery (weeks)	2	179	170	−0.11 (−0.40 to 0.19)	—	0.47	0
Preterm birth (%)	1	104	96	—	1.15 (0.32 to 4.17)	0.83	—
Birth weight (g)	2	179	170	−209 (−314 to −104)	—	<0.001	0
Macrosomia (%)	2	179	170	—	0.33 (0.13 to 0.81)	0.02	0
Large for gestational age (%)	1	104	96	—	0.44 (0.21 to 0.92)	0.03	—
Small for gestational age (%)	1	104	96	—	1.23 (0.28 to 5.36)	0.78	—
Any neonatal hypoglycaemia (%)	2	178	169	—	0.86 (0.42 to 1.77)	0.68	0
Perinatal mortality (%)	1	104	96	—	0.92 (0.06 to 14.6)	0.95	—
Secondary outcomes							
Fasting blood glucose (mmol/L)	2	179	170	0.15 (0.00 to 0.30)	—	0.04	0
Postprandial blood glucose (mmol/L)	2	179	170	−0.04 (−0.27 to 0.19)	—	0.74	0
Maternal weight gain since entry (kg)	0	—	—	—	—	—	—
Pregnancy induced hypertension (%)	0	—	—	—	—	—	—
Induction (%)	0	—	—	—	—	—	—
Cord C peptide (nmol/L)	0	—	—	—	—	—	—
Cord insulin (pmol/L)	0	—	—	—	—	—	—
1 minute Apgar score <7 (%)	1	103	95	—	0.46 (0.04 to 5.00)	0.52	—
5 minute Apgar score <7 (%)	2	178	169	—	2.77 (0.10 to 67.2)	0.53	—
Obstetric trauma (%)	0	—	—	—	—	—	—
Severe neonatal hypoglycaemia† (%)	0	—	—	—	—	—	—
Neonatal jaundice (%)	0	—	—	—	—	—	—
Neonatal respiratory distress syndrome (%)	0	—	—	—	—	—	—
Stillbirth (%)	1	104	96	—	0.92 (0.06 to 14.6)	0.95	—
Neonatal mortality (%)	1	103	95	—	0 v 0	—	—
NICU admission (%)	2	178	169	—	1.52 (0.65 to 3.55)	0.33	1

I²=Heterogeneity. HbA_{1c}= glyated haemoglobin. NICU=neonatal intensive care unit.*Estimated using a random effects model because I²>50%


†Defined by authors or requiring intravenous glucose or NICU admittance.

Figures



*Instrumental variable fixed effects model

Fig 1 Forest plots of birth weight in the meta-analyses comparing glibenclamide and metformin with insulin or with each other in women with gestational diabetes



*Mantel-Haenszel fixed effects model

Fig 2 Forest plots of any neonatal hypoglycaemia in the meta-analyses comparing glibenclamide and metformin with insulin or with each other in women with gestational diabetes



Nº Ref.:MA843673/16

RESOLUCIÓN EXENTA RW Nº 6725/17
Santiago, 7 de abril de 2017

VISTO ESTOS ANTECEDENTES: la solicitud de D. Leonardo Lucchini Servetto, Responsable Técnico y D. Joao Marques Simoes, Representante Legal de Laboratorios Andrómaco S.A., ingresada bajo la referencia Nº MA843673, de fecha de 27 de diciembre de 2016, mediante la cual solicita nuevo contenido de envase para el producto farmacéutico GLIBENCLAMIDA COMPRIMIDOS 5 mg, Registro Sanitario Nº F-2414/14;

CONSIDERANDO:

PRIMERO: que, mediante la presentación de fecha 27 de diciembre de 2016, se solicitó nuevo contenido de envase para el registro sanitario Nº F-2414/14 del producto farmacéutico GLIBENCLAMIDA COMPRIMIDOS 5 mg.

SEGUNDO: que, consta el pago de los derechos arancelarios correspondientes, mediante el comprobante de recaudación Nº 2016122744752617, emitido por Tesorería General de la República con fecha 27 de diciembre de 2016; y

TENIENDO PRESENTE: las disposiciones del artículo 96º del Código Sanitario; del Reglamento del Sistema Nacional de Control de Productos Farmacéuticos, aprobado por el Decreto Supremo Nº 3 de 2010 del Ministerio de Salud; en uso de las facultades que me confieren los artículos 59º letra b) y 61º letra b), del Decreto con Fuerza de Ley Nº 1, de 2005 y las facultades delegadas por la Resolución Exenta Nº 292 de 12 de febrero de 2014 del Instituto de Salud Pública de Chile, dicto la siguiente:

R E S O L U C I Ó N

1.- **AUTORIZÁSE** el nuevo contenido de envase para el producto farmacéutico **GLIBENCLAMIDA COMPRIMIDOS 5 mg**, Registro Sanitario Nº F-2414/14, concedido a Laboratorios Andrómaco S.A., manteniendo los contenidos de envase anteriormente autorizados.

Venta Público: Envase autorizado en el registro Sanitario que contiene 1 - 90 comprimidos, más folleto de información al paciente y sello de seguridad.

Muestra Médica: Envase autorizado en el registro que contiene 1 - 90 comprimidos, más folleto de información al paciente y sello de seguridad.

Envase Clínico: Envase autorizado en el registro Sanitario que contiene 50 - 2000 comprimidos, más folleto de información al paciente y sello de seguridad.

La presente resolución podrá ser validada en www.ispdocel.ispch.cl con el siguiente identificador:
Código de Verificación: **F0CCE13ADDE5940504258097007E78ED**



2.- Los rótulos del producto indicado deben corresponder exactamente en su texto y distribución a lo autorizado en el registro sanitario y cualquier modificación deberá comunicarse oportunamente a este Instituto.

3.- DÉJASE ESTABLECIDO que la información evaluada en la solicitud para la aprobación de esta modificación al registro sanitario, corresponde a la entregada por el solicitante, el cual se hace responsable de la veracidad de los documentos que adjunta, conforme a lo dispuesto en el Art.210° del Código Penal y que la información proporcionada deberá estar a disposición de la Autoridad Sanitaria, para su verificación, cuando ésta lo requiera.

ANÓTESE Y COMUNÍQUESE



DRA. Q.F. HELEN ROSENBLUTH LÓPEZ
JEFA (S) DEPARTAMENTO AGENCIA NACIONAL DE MEDICAMENTOS
INSTITUTO DE SALUD PÚBLICA DE CHILE

La presente resolución podrá ser validada en www.ispdocel.ispch.cl con el siguiente identificador: Código de Verificación: **F0CCE13ADDE5940504258097007E78ED**



GOBIERNO DE CHILE
MINISTERIO DE SALUD

INSTITUTO DE SALUD PUBLICA

TTA/AMM/TCM/ras
B11/ Ref.: 710/04

SANTIAGO, 07.05.2004*003489


VISTO ESTOS ANTECEDENTES: la presentación de Laboratorios Andrómaco S.A., por la que solicita **nuevo rotulado gráfico** para el producto farmacéutico GLIBENCLAMIDA COMPRIMIDOS 5 mg, registro sanitario N° F-2414/99; y

TENIENDO PRESENTE: las disposiciones de los artículos 94 y 102 del Código Sanitario; del Reglamento del Sistema Nacional de Control de Productos Farmacéuticos, Alimentos de Uso Médico y Cosméticos aprobados por el decreto supremo N° 1876 de 1995 del Ministerio de Salud y los artículos 37 letra b) y 39 letra b) del decreto ley N° 2763 de 1979, y las facultades delegadas por la resolución N° 102 de 1996, del Instituto de Salud Pública de Chile, dicto la siguiente:

RESOLUCIÓN

1.- AUTORIZÁSE el proyecto de rotulado gráfico para el producto farmacéutico GLIBENCLAMIDA COMPRIMIDOS 5 mg, registro sanitario N° F-2414/99, concedido a Laboratorios Andrómaco S.A., el cual debe conformar al anexo timbrado de la presente resolución, sin perjuicio de cumplir lo dispuesto en el artículo N° 49 del Reglamento del Sistema Nacional de Control de Productos Farmacéuticos, Alimentos de Uso Médico y Cosméticos.

ANÓTESE Y COMUNÍQUESE



DRA. Q.F. PAMELA MILLA NANJARÍ
JEFA DEPARTAMENTO CONTROL NACIONAL
INSTITUTO DE SALUD PÚBLICA DE CHILE

DISTRIBUCIÓN:

- Interesado
- C.I.S.P.
- Unidad de Procesos
- Archivo





LABORATORIOS ANDROMACO S.A.

INSTITUTO DE SALUD PUBLICA
Departamento Control Nacional
Sección Registro

PROYECTO DE ROTULADO GRAFICO

ENVASE VENTA PUBLICO

GLIBENCLAMIDA COMPRIMIDOS 5 mg

Rotulado gráfico del estuche:

Cara Nº 1:

GLIBENCLAMIDA
5 mg

X Comprimidos

Laboratorios Andrómaco S.A.

INSTITUTO DE SALUD PUBLICA
DEPARTAMENTO DE CONTROL NACIONAL
REGISTRO Nº F-2414/99

MANTENGASE FUERA DEL
ALCANCE DE LOS NIÑOS

VENTA BAJO RECETA MEDICA
EN ESTABLECIMIENTOS
TIPO A

Cara Nº2:

Cada comprimido contiene:

Glibenclamida

5 mg

Excipientes

C.S.

Registro I.S.P. Nº F-2414/99

Advertencia:

Despáchese sólo con receta médica y por una sola vez, inutilizándola con timbre impreso, salvo que el facultativo autorice su uso continuado por un período determinado, al término del cual se hará la inutilización exigida.

Cara Nº3:

Administración y dosis vía oral, según prescripción médica.

Manténgase fuera del alcance de los niños, en lugar fresco y seco, a no más de 25°C.

Venta bajo receta médica en establecimientos tipo A.

DEPARTAMENTO CONTROL NACIONAL

Nº. REF

710/04

15 ABR 2004

UNIDAD DE MODIFICACIONES

AV.QUILIN 5273 - TELEFONO 510 8500 - FAX 552 9363
SANTIAGO - CHILE



LABORATORIOS ANDROMACO S.A.

INSTITUTO DE SALUD PUBLICA
Departamento Control Nacional
Sección Registro

Cara Nº4:

Elaborado y distribuido en Chile por
Laboratorios Andrómaco S.A.
Avda. Quilín 5273, Peñalolen, Santiago.

Aleta superior:

GLIBENCLAMIDA
5 mg

X Comprimidos

Aleta inferior:

Serie:

Vence:

INSTITUTO DE SALUD PUBLICA
DEPARTAMENTO DE CONTROL NACIONAL
REGISTRO Nº F-2414199

MANTENGASE FUERA DEL
ALCANCE DE LOS NIÑOS

VENTA BAJO RECETA MEDICA
EN ESTABLECIMIENTOS
TIPO A

DEPARTAMENTO CONTROL NACIONAL

Nº. REF 710/04

15 ABR 2004

UNIDAD DE MODIFICACIONES



LABORATORIOS ANDROMACO S.A.

INSTITUTO DE SALUD PUBLICA
Departamento Control Nacional
Sección Registro

Rotulado gráfico del blister:

GLIBENCLAMIDA
5 mg

Comprimidos

Serie:

Vence:

Laboratorios Andrómaco S.A.

Reg. I.S.P. N°:

INSTITUTO DE SALUD PUBLICA
DEPARTAMENTO DE CONTROL NACIONAL
REGISTRO N° F-2414199

**MANTENGASE FUERA DEL
ALCANCE DE LOS NIÑOS**

VENTA BAJO RECETA MEDICA
EN ESTABLECIMIENTOS
TIPO A

DEPARTAMENTO CONTROL NACIONAL

N°. REF

710104

15 ABR 2004

UNIDAD DE MODIFICACIONES



LABORATORIOS ANDROMACO S.A.

INSTITUTO DE SALUD PUBLICA
Departamento Control Nacional
Sección Registro

Proyecto de rotulado gráfico del envase clínico:

GLIBENCLAMIDA
5 mg

X Comprimidos

Cada comprimido contiene:
Glibenclamida
Excipientes

Registro I.S.P. N° F-2414/99

Envase clínico sólo para
establecimientos Asistenciales

Almacenar en lugar fresco y seco, a no más de 25°C

Serie:

Vence:

Elaborado y distribuido en Chile por
Laboratorios Andrómaco S.A.
Avda. Quilín 5273, Peñalolen, Santiago.

INSTITUTO DE SALUD PUBLICA
DEPARTAMENTO DE CONTROL NACIONAL
REGISTRO N° **F-2414/99**

**MANTENGASE FUERA DEL
ALCANCE DE LOS NIÑOS**

5 mg
c.s.

**ENVASE CLINICO SOLO
PARA ESTABLECIMIENTOS
MEDICO - ASISTENCIALES**

DEPARTAMENTO CONTROL NACIONAL

N°. REF **710104**

15 ABR 2004

UNIDAD DE MODIFICACIONES

Nº Oficina Partes y fecha	
Arancel <i>49813</i>	
Autorizado fecha	0151 18 JUN. 1981

SOLICITUD PARA AUTORIZACIÓN DE MODIFICACIÓN DEL REGISTRO SANITARIO DE PRODUCTOS
FARMACÉUTICOS, ALIMENTOS DE USO MÉDICO Y COSMÉTICOS

(Esta solicitud se llenará en cuadruplicado)

8 de Junio de 1981

- I. Fecha
Nombre del Propietario o Representante legal **BENGUEREL E HIJOS LTDA.**
Nombre del Director Técnico **ANDRÉS ANDRACA CORTES**
Razón Social del Establecimiento **LABORATORIO BENGUEREL**
Laboratorio ☒ Droguería ☐ Farmacia ☐ Depósito Veterinario ☐
Otros ☐
Domicilio Legal **PLAZA VALDIVIESO SOLAR 2409** Fono: **50068**

- II. De acuerdo a las disposiciones del Código Sanitario y del Reglamento de Productos Farmacéuticos, Alimentos de Uso Médico y Cosméticos; solicita del Servicio Nacional de Salud, la autorización para modificar el registro sanitario del producto..... **GLIBENCLAMIDA Comprimidos**

registrado en este Servicio bajo Registro Nº **12.753** Resolución/fecha **390 del 29 Marzo de 1976** en lo siguiente:

- a) Presentación o contenido del envase ☒ y **1.000 comp. Clínicos para SERVICIOS ASISTENCIALES.**
Nuevo (s) envase (s) de **500**
Manteniendo los envases de **vidrio y plástico por 30 comprimidos.**
Cancelando los envases de
- b) Tipo de envase ☒ **ENVASE BLISTER - PACK IMPRESO EN ESTUCHE DE 30 Comprimidos.**
Se cambia a
- c) Rotulado gráfico o textos de envases ☐
(Se adjunta en cuadruplicado)
- d) Folleto para información médica ☐
(Se adjunta en cuadruplicado)
- e) Propaganda ☐
(Se adjunta en cuadruplicado)



Instituto de Salud Pública de Chile
DEPARTAMENTO DE CONTROL NACIONAL
FOLLETO PARA INFORMACIÓN MÉDICA

DRA. RAQUEL GONZALEZ DIEZ
JEFE DEPARTAMENTO CONTROL NACIONAL
INSTITUTO DE SALUD PÚBLICA DE CHILE

Nombre y firma del
Director Técnico
ANDRÉS ANDRACA C.
Químico Farmacéutico
Laboratorio Benguerel

DIRECTOR TÉCNICO
LABORATORIO BENGUEREL

Nombre y firma del
Representante Legal
A. P. BENGUEREL E HIJOS LTDA.
LABORATORIO BENGUEREL

REPUBLICA DE CHILE
MINISTERIO DE SALUD
INSTITUTO DE SALUD PUBLICA
DE CHILE
DEPTO. CONTROL NACIONAL

USO EXCLUSIVO DEL I.S.P.

Nº Oficina Partes y fecha	
Arancel 498	0057
Autorizado fecha	16 MAR. 1982

SOLICITUD PARA AUTORIZACION DE MODIFICACION DEL REGISTRO SANITARIO DE PRODUCTOS FARMACEUTICOS, ALIMENTOS DE USO MEDICO Y COSMETICOS

(Esta solicitud se llenará en cuádruplicado)

I Fecha 27 de Enero de 1982
Nombre del Propietario o Representante legal LABORATORIO BENGUEREL
Nombre del Director Técnico Y Apoderado: ANDRES ANDRACA CORTES
Razón Social del Establecimiento LABORATORIO BENGUEREL LTDA.
Laboratorio ☒ XX Droguería ☐ Farmacia ☐ Depósito Veterinario ☐
Otros ☐
Domicilio Legal PLAZA VALDIVIESO SOLAR Nº 2409 SANTIAGO Fono: 50068

II De acuerdo a las disposiciones del Código Sanitario y del Reglamento de Productos Farmacéuticos, Alimentos de Uso Médico y Cosméticos; solicita del Instituto de Salud Pública de Chile la autorización para modificar el registro sanitario del producto GLIBENCLAMIDA Comprimidos

registrado bajo Nº 12.753 ó Resolución/fecha Nº 390 del 29-Marzo -1976 en lo siguiente:

a) Presentación o contenido del envase ☒ XX
Nuevo(s) envase(s) de 60 y 100 Comprimidos en Blister/Tubo plástico/Frasco vidrio
Manteniendo los envases de 30 Comprimidos en Blister/Tubo plástico/Frasco vidrio.
Cancelando los envases de _____

b) Tipo de envase ☐
Se cambia a _____

c) Rotulado gráfico o textos de envases ☐
(Se adjunta en cuádruplicado)

d) Folleto para información médica ☐
(Se adjunta en cuádruplicado)

e) Propaganda ☐
(Se adjunta en cuádruplicado)

Instituto de Salud Pública de Chile
DEPARTAMENTO DE CONTROL NACIONAL

AUTORIZADO
DRA. RAQUEL GONZALEZ DIEZ
JEFE DEPARTAMENTO CONTROL NACIONAL
INSTITUTO DE SALUD PUBLICA DE CHILE

Nombre y firma del
Director Técnico
ANDRES ANDRACA C.
Químico Farmacéutico
Laboratorio Benguerel
HEMUSI Ltda. - Porvenir 964/968, F. 226039, Stgo.

DIRECTOR TECNICO
LABORATORIO BENGUEREL

Nombre y firma del
Representante Legal
ANDRES ANDRACA C.
Químico Farmacéutico
Laboratorio Benguerel
LABORATORIO BENGUEREL
Plaza Valdivieso Solar 2409
SANTIAGO